PBI-05204, a supercritical CO2 extract of Nerium oleander, inhibits growth of human pancreatic cancer via targeting the PI3K/mTOR pathway Yong PanPatrea RheaPeiying Yang PRECLINICAL STUDIES Open access 06 December 2014 Pages: 271 - 279
Chemotherapy in vivo against M109 murine lung carcinoma with cytochalasin B by localized, systemic, and liposomal administration Matthew TrendowskiJoan M. MitchellThomas P. Fondy PRECLINICAL STUDIES Open access 06 January 2015 Pages: 280 - 289
Chemotherapy with cytochalasin congeners in vitro and in vivo against murine models Matthew TrendowskiJoan M. MitchellThomas P. Fondy PRECLINICAL STUDIES Open access 07 January 2015 Pages: 290 - 299
The FLT3 and PDGFR inhibitor crenolanib is a substrate of the multidrug resistance protein ABCB1 but does not inhibit transport function at pharmacologically relevant concentrations Trevor J. MathiasKarthika NatarajanMaria R. Baer PRECLINICAL STUDIES 20 January 2015 Pages: 300 - 309
Treatment effect of buparlisib, cetuximab and irradiation in wild-type or PI3KCA-mutated head and neck cancer cell lines Laura LattanzioFederica TonissiCristiana Lo Nigro PRECLINICAL STUDIES 22 January 2015 Pages: 310 - 320
A phase I pharmacokinetic and safety analysis of epothilone folate (BMS-753493), a folate receptor targeted chemotherapeutic agent in humans with advanced solid tumors P. P. PeethambaramL. C. HartmannL. Alland PHASE I STUDIES 08 November 2014 Pages: 321 - 331
A phase I study of farletuzumab, a humanized anti-folate receptor α monoclonal antibody, in patients with solid tumors Yasutsuna SasakiKeisuke MiwaNoriyuki Katsumata PHASE I STUDIES Open access 09 November 2014 Pages: 332 - 340
Pharmacokinetic study of aldoxorubicin in patients with solid tumors Monica M. MitaRonald B. NataleAlain C. Mita PHASE I STUDIES Open access 12 November 2014 Pages: 341 - 348
Phase I study of XL281 (BMS-908662), a potent oral RAF kinase inhibitor, in patients with advanced solid tumors Mark A. DicksonMichael S. GordonGary K. Schwartz PHASE I STUDIES 05 December 2014 Pages: 349 - 356
Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer Jordi RodónMichael CarducciJose Baselga PHASE I STUDIES Open access 23 December 2014 Pages: 357 - 370
A phase I and pharmacodynamic study of the histone deacetylase inhibitor belinostat plus azacitidine in advanced myeloid neoplasia Olatoyosi OdenikeAnna HalpernWendy Stock PHASE I STUDIES 09 December 2014 Pages: 371 - 379
Phase I study of amatuximab, a novel monoclonal antibody to mesothelin, in Japanese patients with advanced solid tumors Yasuhito FujisakaTakayasu KurataKazuhiko Nakagawa PHASE I STUDIES Open access 12 December 2014 Pages: 380 - 388
Phase I study of the novel Cdc2/CDK1 and AKT inhibitor terameprocol in patients with advanced leukemias R. TibesK. T. McDonaghT. C. Shea PHASE I STUDIES 19 December 2014 Pages: 389 - 396
Phase 1/2 study of orteronel (TAK-700), an investigational 17,20-lyase inhibitor, with docetaxel–prednisone in metastatic castration-resistant prostate cancer Daniel P. PetrylakJitendra G. GandhiGlenn Liu PHASE I STUDIES 04 January 2015 Pages: 397 - 408
A phase 1 dose escalation study of BI 831266, an inhibitor of Aurora kinase B, in patients with advanced solid tumors Christian DittrichMichael A. FridrikRichard Greil PHASE I STUDIES Open access 23 December 2014 Pages: 409 - 422
Phase 1 study of the oral histone deacetylase inhibitor abexinostat in patients with Hodgkin lymphoma, non-Hodgkin lymphoma, or chronic lymphocytic leukaemia Franck MorschhauserLouis TerriouVincent Ribrag PHASE I STUDIES 21 January 2015 Pages: 423 - 431
Phase 1b study of the oral gemcitabine ‘Pro-drug’ LY2334737 in combination with capecitabine in patients with advanced solid tumors Jeffrey R. InfanteKarim A. BenhadjiAlex A. Adjei PHASE I STUDIES 03 February 2015 Pages: 432 - 439
First-in-human phase 1 study of filanesib (ARRY-520), a kinesin spindle protein inhibitor, in patients with advanced solid tumors Patricia M. LoRussoPriscila H. GoncalvesEdward A. Sausville PHASE I STUDIES 17 February 2015 Pages: 440 - 449
Safety, tolerability, and pharmacokinetics of single and multiple doses of intravenous cixutumumab (IMC-A12), an inhibitor of the insulin-like growth factor-I receptor, administered weekly or every 2 weeks in patients with advanced solid tumors C. S. HiganoJ. BerlinJ. M. Mehnert PHASE I STUDIES 07 March 2015 Pages: 450 - 462
A phase 1 study of the sachet formulation of the oral dual PI3K/mTOR inhibitor BEZ235 given twice daily (BID) in patients with advanced solid tumors Johanna C. BendellCarla KurkjianSuzanne F. Jones PHASE I STUDIES 25 February 2015 Pages: 463 - 471
Phase-I dose finding and pharmacokinetic study of the novel hydrophilic camptothecin ST-1968 (namitecan) in patients with solid tumors M. JoergerD. HessC. Sessa PHASE I STUDIES 20 February 2015 Pages: 472 - 479
A phase II study of sulforaphane-rich broccoli sprout extracts in men with recurrent prostate cancer Joshi J. AlumkalRachel SlottkeMotomi Mori PHASE II STUDIES 29 November 2014 Pages: 480 - 489
Phase II trial of combination therapy of gemcitabine plus anti-angiogenic vaccination of elpamotide in patients with advanced or recurrent biliary tract cancer Masato MatsuyamaH. IshiiY. Sasaki PHASE II STUDIES Open access 13 December 2014 Pages: 490 - 495
Preliminary efficacy, safety, pharmacokinetics, pharmacodynamics and quality of life study of pegylated recombinant human arginase 1 in patients with advanced hepatocellular carcinoma Thomas YauPaul N. ChengRonnie T. Poon PHASE II STUDIES 10 February 2015 Pages: 496 - 504
Everolimus and pasireotide for advanced and metastatic hepatocellular carcinoma Hanna K. SanoffRichard KimBert H. O’Neil PHASE II STUDIES 23 January 2015 Pages: 505 - 509
Infected complex renal cysts during crizotinib therapy in a patient with non–small cell lung cancer positive for ALK rearrangement Yasuto YoneshimaIsamu OkamotoYoichi Nakanishi SHORT REPORT 30 November 2014 Pages: 510 - 512
Aptamers as a novel tool for diagnostics and therapy Onat KadiogluAnna Helena MalczykThomas Efferth REVIEW 01 February 2015 Pages: 513 - 520
Axitinib plasma pharmacokinetics and ethnic differences Ying ChenAkiyuki SuzukiYazdi K. Pithavala REVIEW 08 February 2015 Pages: 521 - 532